Status:
COMPLETED
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
Lead Sponsor:
Pfizer
Conditions:
HIV Infection
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum. The study will also evaluate ...
Eligibility Criteria
Inclusion
- HIV infection
- Second trimester of pregnancy
Exclusion
- Major current or prior history of obstetrical complications
- Serious current medical diseases
- Evidence of HIV virus resistance to antiretroviral agents
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00246610
Start Date
March 1 2006
End Date
November 1 2007
Last Update
April 28 2011
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Jacksonville, Florida, United States, 32209
2
Pfizer Investigational Site
Miami, Florida, United States, 33136
3
Pfizer Investigational Site
Metairie, Louisiana, United States, 70006
4
Pfizer Investigational Site
Detroit, Michigan, United States, 48201